Literature DB >> 35373581

A System Based on Novel Parainfluenza Virus PIV5-L for Efficient Gene Delivery of B-Lymphoma Cells.

Xiaoqing Liu1, Lilan Zheng1, Ting Wang2, Ying Li1, Bingbing Wu3, Shujuan Du1, Qing Zhu1, Caixia Zhu1, Yuyan Wang1, Rong Zhang1, Fang Wei3, Qiliang Cai1,2.   

Abstract

Aggressive B-cell lymphoma is one of the most common types of blood malignancy. Robust delivery of genes of interest into target cells, long-term gene expression, and minimal risk of secondary effects are highly desirable for translational medicine including gene therapy and studies on gene function. However, efficient gene delivery into viral or nonviral B-lymphoma cells remains a challenge. Here, we report a strategy for inducing foreign gene expression in B-lymphoma cells by using a vector based on the novel parainfluenza virus PIV5-L (a strain isolated from B cells) that enabled us to study and control the function of a gene product within B-lymphoma cells. Using enhanced green fluorescent protein (eGFP) as a reporter, we successfully rescued PIV5-L and established a one-step system to generate PIV5-L virus-like particles (L-VLPs) with efficient delivery into a broad spectrum of susceptible B-lymphoma cell lines, including Epstein-Barr virus (EBV)- or Kaposi's sarcoma-associated herpesvirus (KSHV)-transformed B-lymphoblastoid cells. Similar to lentiviral vector, the L-VLP highly expressed exogenous genes and remained stable for long periods without obvious negative effects on cell viability. Taken together, these data demonstrate that the PIV5-L-based system provides a potential new strategy for the delivery of desirable genes and the treatment of cancer. IMPORTANCE B-cell lymphoma is a common aggressive neoplastic disorder of lymphocytes. Delivery of genes of interest into B cells, particularly virus-mediated B-lymphoma cells, is still a challenge. In this study, we report that a system (L-VLP) based on the parainfluenza virus PIV5-L strain isolated from B cells had highly expressed exogenous genes and remained stable without obvious cell toxicity, which provides a potential new strategy for gene delivery and treatment of B-cell cancer.

Entities:  

Keywords:  B-cell lymphoma; PIV5-L; gene delivery

Mesh:

Year:  2022        PMID: 35373581      PMCID: PMC9044942          DOI: 10.1128/jvi.00257-22

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  26 in total

1.  Requirements for budding of paramyxovirus simian virus 5 virus-like particles.

Authors:  Anthony P Schmitt; George P Leser; David L Waning; Robert A Lamb
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment.

Authors:  Alina Nicolae; Stefania Pittaluga; Shahed Abdullah; Seth M Steinberg; Thu Anh Pham; Theresa Davies-Hill; Liqiang Xi; Mark Raffeld; Elaine S Jaffe
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

Review 3.  Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Manli Jiang; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2017-01-29       Impact factor: 2.929

4.  Exchange of P/V genes between two non-cytopathic simian virus 5 variants results in a recombinant virus that kills cells through death pathways that are sensitive to caspase inhibitors.

Authors:  Patrick J Dillon; Elizabeth K Wansley; Virginia A Young; Martha A Alexander-Miller; Griffith D Parks
Journal:  J Gen Virol       Date:  2006-12       Impact factor: 3.891

Review 5.  Lymphoma classification update: B-cell non-Hodgkin lymphomas.

Authors:  Manli Jiang; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2017-04-24       Impact factor: 2.929

6.  Roles for the cytoplasmic tails of the fusion and hemagglutinin-neuraminidase proteins in budding of the paramyxovirus simian virus 5.

Authors:  David L Waning; Anthony P Schmitt; George P Leser; Robert A Lamb
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Single-dose vaccination of a recombinant parainfluenza virus 5 expressing NP from H5N1 virus provides broad immunity against influenza A viruses.

Authors:  Zhuo Li; Jon D Gabbard; Alaina Mooney; Xiudan Gao; Zhenhai Chen; Ryan J Place; S Mark Tompkins; Biao He
Journal:  J Virol       Date:  2013-03-20       Impact factor: 5.103

Review 8.  Parainfluenza virus 5-vectored vaccines against human and animal infectious diseases.

Authors:  Zhenhai Chen
Journal:  Rev Med Virol       Date:  2018-01-05       Impact factor: 6.989

9.  Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine.

Authors:  Dong An; Kun Li; Dawne K Rowe; Maria Cristina Huertas Diaz; Emily F Griffin; Ashley C Beavis; Scott K Johnson; Ian Padykula; Cheryl A Jones; Kelsey Briggs; Geng Li; Yuan Lin; Jiachen Huang; Jarrod Mousa; Melinda Brindley; Kaori Sakamoto; David K Meyerholz; Paul B McCray; S Mark Tompkins; Biao He
Journal:  Sci Adv       Date:  2021-07-02       Impact factor: 14.957

10.  Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection.

Authors:  Kun Li; Zhuo Li; Christine Wohlford-Lenane; David K Meyerholz; Rudragouda Channappanavar; Dong An; Stanley Perlman; Paul B McCray; Biao He
Journal:  mBio       Date:  2020-04-07       Impact factor: 7.867

View more
  1 in total

Review 1.  Virus-like Particles as Nanocarriers for Intracellular Delivery of Biomolecules and Compounds.

Authors:  Junyao He; Linying Yu; Xiaodi Lin; Xiaoyan Liu; Yanming Zhang; Fan Yang; Wen Deng
Journal:  Viruses       Date:  2022-08-28       Impact factor: 5.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.